CARIBOU BIOSCIENCES INC (CRBU)
Health Care · CRISPR-engineered cell therapy · NASDAQ
Caribou develops off-the-shelf CRISPR-engineered CAR-T cell therapies designed to make cellular immunotherapy faster, cheaper, and accessible to more blood cancer patients.
What CARIBOU BIOSCIENCES INC does
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company developing allogeneic (off-the-shelf) CAR-T cell therapies for patients with hematologic malignancies. The company leverages its proprietary chRDNA (CRISPR hybrid RNA-DNA) genome-editing technology to engineer enhanced cell therapies with checkpoint disruption and immune cloaking strategies. Currently advancing two clinical-stage allogeneic CAR-T candidates: vispa-cel (anti-CD19) in Phase 1 for relapsed/refractory B-NHL, and CB-011 (anti-BCMA) in Phase 1 for relapsed/refractory multiple myeloma.
Themes: ["CAR-T cell therapy","CRISPR genome editing","Allogeneic cell therapy","Hematologic malignancies / blood cancers","Non-Hodgkin lymphoma","Multiple myeloma"]
Fundamentals
- Price$1.94 as of 2026-07-09 close
- Market cap$192M as of 2026-07-10
- 1-year return+21.3% as of 2026-07-09 close
- Net margin-1189.1% as of 2026-07-10
- ROE-100.1% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+13.0% as of 2026-07-10
- Revenue CAGR (3y)-7.0% SEC XBRL
- Beta2.32 as of 2026-07-10
Key risks (from latest filing)
["Clinical-stage company with no approved products; vispa-cel and CB-011 remain in Phase 1 trials with uncertain regulatory approval pathways and efficacy outcomes.","Severe net margin of -1189.14% and substantial accumulated deficit ($621.6M) indicate significant ongoing cash burn with limited runway despite $107.6M in current liquid assets.","Manufacturing and scalability challenges for allogeneic CAR-T therapies; competitive landscape includes established autologous CAR-T (Yescarta, Kymriah) and emerging bispecific antibody therapies."]
Competitors & peers
- Juno Therapeutics (cell therapy, CAR-T)
- Bluebird Bio (cell therapy)
- Precision Biosciences (genome editing, cell therapy)
- Editas Medicine (CRISPR therapeutics)
- CRISPR Therapeutics (CRISPR therapeutics)
- Cellectis (allogeneic CAR-T)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.